Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Nivolumab & Renal cell carcinoma (RCC)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

FDA status

In the context of Nivolumab & Renal cell carcinoma (RCC), the FDA approved nivolumab on 23 November 2015 for patients with advanced Renal cell carcinoma (RCC) who have received prior anti‑angiogenic therapy, based on CheckMate 025, where nivolumab improved overall survival versus everolimus in predominantly Clear Cell Renal Cell Carcinoma (ccRCC) (1, 2, 4)

EMA status

The [European Commission](brain://QMGe2vnxWkWiArAahJp9aA/EuropeanMedi…

References (Sources)

FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis
Xu et al. 2017 Oncologist 22(3): 311-317
Molecular correlates of response to nivolumab at baseline and on treatment in patients with RCC
Ross-Macdonald et al. 2021
Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies
Salama & Moschos 2017 Ann. Oncol. 28: 57–74
Review
Nivolumab for the Treatment of Pts with Metastatic Non Clear Cell RCC: A Single Institutional Experience and Referencese Meta Analysis
Chahoud et al. 2020
Nivolumab in renal cell carcinoma: latest evidence and clinical potential
Mazza et al. 2017 Ther Adv Med Oncol 9(3): 171-181
Review
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
Vano et al. 2022 The Lancet Oncology 23: 612-624
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study
Flippot et al. 2019 JCO 37: 2008–2016

AI Chat

7/1/2026

Chat with our artificial intelligence: